null

null

null

null

null

null

null

null

null

null

null

null

null

0.07x Total Debt / Equity (Conservative)

Low direct sensitivity; minimal long-term debt, but equity dilution via ATM offerings makes cost of capital highly sensitive to rate-driven valuation compression

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Biologic raw material suppliers (bone marrow, placental tissue) with limited qualified vendors; 2) FDA-regulated reagent suppliers concentrated in US/EU

Negligible international revenue; virtually no sovereign currency devaluation exposure as operations are predominantly US-domestic clinical-stage

Primarily US-based; no material international revenue markets identified, so sovereign currency devaluation risk is near-zero currently

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single-source biological material suppliers and specialized GMP contract manufacturers; substitution would require lengthy FDA revalidation

Cloud infrastructure disruption would be moderate; company relies on standard clinical data and regulatory platforms, not proprietary cloud-native architecture

Secondary operations (lab informatics, trial management) could migrate within 60-90 days with significant but recoverable disruption to ongoing trial data pipelines

Low API coupling risk; no proprietary platform integrations identified; primary tech dependencies are off-the-shelf clinical trial management and EHR systems

Low Howey risk; revenue model is product/service-based (cell therapy, licensing); no token or profit-sharing instrument in primary commercial offering

Very High

Moderate HIPAA exposure from patient clinical trial data; limited GDPR risk given minimal EU operations; CCPA applicability low due to small California patient data footprint

Negligible antitrust risk; company is a small-cap clinical-stage biotech with de minimis market share in any defined therapeutic market

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional/grant-based; less than 10% recurring revenue estimated; revenue is episodic from licensing deals, grants, and early commercialization

Primary monetization via IP licensing, technology transfer agreements, and nascent direct product sales of regenerative medicine therapies

Pricing not yet stress-tested at scale; therapy pricing will be subject to hospital formulary negotiation and CMS reimbursement determination, creating ceiling risk

Low near-term pricing power; clinical-stage company dependent on reimbursement approval and competitive landscape in regenerative medicine

63.4% Gross Margin (Premium (>60%))

No free-rider leakage problem identified; no SaaS or platform model; product is proprietary biological therapy requiring purchase

Revenue growth is currently headcount-linear due to lab-based manufacturing; scaling requires proportional GMP facility and scientific staff investment

High marginal cost of growth; each incremental therapy unit requires biological inputs, GMP processing, and regulatory compliance costs with limited automation leverage

Not applicable; company operates no franchise network

At 10x scale, CAC likely declines as hospital network relationships mature, but COGS remains high; unit economics improve only with manufacturing automation investment

No meaningful network effects; product value does not increase with additional users; competitive moat relies on IP and clinical data exclusivity

-76.8% Return on Assets (Negative equity)

Moderate-low recession resistance; elective regenerative therapies face deferral risk, though wound care and orthopedic indications have non-discretionary components

Hospitals and specialty clinics (orthopedic, wound care, fertility centers) representing institutional B2B purchasing decisions

Government and academic research institutions providing grant funding; concentration risk exists if NIH/DOD grant renewal fails

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being deployed toward future-state GMP manufacturing and clinical trial infrastructure, not legacy operations; high burn rate with no legacy asset base to reallocate from

0001187953

CELZ